The glutaminolysis-related genes, including ASCT2 and GDH-encoding GLUD, are suggested as biomarkers of the efficacy of SLC7A11 (xCT)-targeted therapy for heterogeneous head and neck squamous cell carcinoma tumors (Okazaki et al., 2019). This evidence concerns the gene GLUD1 and head and neck squamous cell carcinoma.